NASDAQ:KALA KALA BIO (KALA) Stock Price, News & Analysis $4.06 +0.02 (+0.50%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$4.06 0.00 (-0.12%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About KALA BIO Stock (NASDAQ:KALA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get KALA BIO alerts:Sign Up Key Stats Today's Range$3.92▼$4.1250-Day Range$2.94▼$6.9252-Week Range$2.92▼$11.20Volume14,691 shsAverage Volume93,402 shsMarket Capitalization$26.20 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingBuy Company OverviewKALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Read More… KALA BIO Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreKALA MarketRank™: KALA BIO scored higher than 68% of companies evaluated by MarketBeat, and ranked 361st out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKALA BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKALA BIO has only been the subject of 1 research reports in the past 90 days.Read more about KALA BIO's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for KALA BIO are expected to grow in the coming year, from ($10.84) to ($6.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KALA BIO is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KALA BIO is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKALA BIO has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about KALA BIO's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.62% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in KALA BIO has recently increased by 43.12%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKALA BIO does not currently pay a dividend.Dividend GrowthKALA BIO does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.35 Percentage of Shares Shorted7.62% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in KALA BIO has recently increased by 43.12%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.50 News SentimentKALA BIO has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for KALA BIO this week, compared to 2 articles on an average week.Search Interest1 people have searched for KALA on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, KALA BIO insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.32% of the stock of KALA BIO is held by insiders.Percentage Held by InstitutionsOnly 24.61% of the stock of KALA BIO is held by institutions.Read more about KALA BIO's insider trading history. Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address KALA Stock News HeadlinesQ1 Earnings Forecast for KALA BIO Issued By HC WainwrightMay 27 at 1:57 AM | americanbankingnews.comHC Wainwright Cuts KALA BIO (NASDAQ:KALA) Price Target to $12.00May 25 at 1:43 AM | americanbankingnews.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 28, 2025 | Porter & Company (Ad)KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | finance.yahoo.comKALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | markets.businessinsider.comKALA BIO to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | finance.yahoo.comKala Bio announces CEO departure, appoints interim leaderFebruary 13, 2025 | msn.comKALA BIO, Inc.: KALA BIO Announces Chief Executive Officer TransitionFebruary 12, 2025 | finanznachrichten.deSee More Headlines KALA Stock Analysis - Frequently Asked Questions How have KALA shares performed this year? KALA BIO's stock was trading at $6.94 at the beginning of the year. Since then, KALA shares have decreased by 41.5% and is now trading at $4.06. View the best growth stocks for 2025 here. How were KALA BIO's earnings last quarter? KALA BIO, Inc. (NASDAQ:KALA) released its quarterly earnings data on Friday, March, 28th. The company reported ($1.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.28) by $0.54. When did KALA BIO's stock split? Shares of KALA BIO reverse split on the morning of Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did KALA BIO IPO? KALA BIO (KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. Who are KALA BIO's major shareholders? Top institutional investors of KALA BIO include ADAR1 Capital Management LLC (4.63%), Woodline Partners LP (4.01%), AIGH Capital Management LLC (3.04%) and Readystate Asset Management LP (0.66%). Insiders that own company stock include Bros Advisors Lp Baker, Mark T Iwicki, Todd Bazemore, Mary Reumuth, Eric Trachtenberg and Darius Kharabi. View institutional ownership trends. How do I buy shares of KALA BIO? Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of KALA BIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include Plug Power (PLUG), Ovid Therapeutics (OVID), Fortress Biotech (FBIO), FuelCell Energy (FCEL), Workhorse Group (WKHS), Lipocine (LPCN) and Comtech Telecommunications (CMTL). Company Calendar Last Earnings3/28/2025Today5/27/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KALA CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$15.00 Low Stock Price Target$12.00 Potential Upside/Downside+232.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-448.61% Return on Assets-69.37% Debt Debt-to-Equity Ratio3.18 Current Ratio2.15 Quick Ratio2.15 Sales & Book Value Annual Sales$3.89 million Price / Sales6.73 Cash FlowN/A Price / Cash FlowN/A Book Value$2.79 per share Price / Book1.46Miscellaneous Outstanding Shares6,452,000Free Float5,584,000Market Cap$26.20 million OptionableNot Optionable Beta-1.91 Social Links 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:KALA) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.